Take-Home Message {#FPar12}
=================

This manuscript is the first report on a new biomarker, urinary chemokine ligand CCL14, which is a predictor of persistent stage 3 AKI. CCL14 has never been identified in the pathobiology of AKI before. The role of this chemokine is entirely consistent with what is known about the development of renal damage and repair, in particular macrophage trafficking and subsequent fibrosis.

Introduction {#Sec1}
============

Acute kidney injury (AKI) is a global problem affecting more than 10% of all hospitalized patients and approaching two-thirds of those admitted to intensive care units, with survival related not only to the severity, but also to the duration of renal dysfunction \[[@CR1]--[@CR3]\]. Recent evidence suggests that two-thirds of patients with AKI resolve their renal dysfunction within 3--7 days whereas those who persist have dramatically reduced survival over the following year \[[@CR4]\]. Persistence of AKI is of grave importance in that it increases an individual's risk of developing chronic kidney disease (CKD) and the consequences thereof \[[@CR5]\]. This link between AKI and CKD has been established over the last decade and specific recommendations for the management of patients with AKI have been proposed in order to potentially influence this transition \[[@CR5], [@CR6]\]. It follows that early identification of individuals at risk of persistent AKI would enable appropriate delivery of these proposed interventions, but also may identify individuals where newer therapies to attenuate AKI could be targeted.

Not only is persistence of AKI relevant to longer term outcomes, clinical decision-making is also critically affected by physician expectations surrounding renal recovery and the decision of when to initiate renal replacement therapy (RRT). Currently this is almost totally dependent on clinical expectations as to the likelihood of recovery with no available diagnostics to aid this decision process. As such, significant controversy exists around the timing of RRT with studies showing that some patients can benefit from the earlier initiation of RRT, while other studies demonstrate that some individuals receive RRT who may not require such treatment as they will recover renal function soon \[[@CR7], [@CR8]\]. Early and reliable identification of those who will recover renal function may enable a more stratified approach to management, thus avoiding the incumbent risks of extracorporeal therapy.

Of equal or even greater importance is that the mechanisms responsible for recovery from AKI are incompletely understood. Recovery following AKI involves dedifferentiation and proliferation of viable cells which then re-epithelialize the nephron. Failure to regenerate lost cells results in a maladaptive repair and fibrosis \[[@CR9]\]. Key mechanisms and triggers for these processes are largely unknown.

In order to find potential markers for persistent AKI, both as candidates for diagnostic testing as well as potential drug targets, we tested novel candidate biomarkers in an international multi-center prospective study to predict persistence of AKI.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The RUBY study is an international prospective observational study aimed at identifying biomarkers associated with the persistence of stage 3 AKI as defined by the KDIGO criteria \[[@CR10]\]. Adult patients in the intensive care unit (ICU) with moderate or severe AKI (stage 2 or 3) and an indwelling urinary catheter were enrolled from June 2013 through May 2014. Both serum creatinine and urine output criteria were used to determine KDIGO AKI stage \[[@CR10]\]. Patients were enrolled within 36 h of meeting the KDIGO criteria as determined by the investigator based on serum creatinine and urine output data available at the time of enrollment. Any patients later determined not to be at stage 2 or 3 at enrollment by retrospective analysis were retained in the primary analysis cohort based on the intent to diagnose principle \[[@CR11]\]. Patients were excluded if they had a prior kidney transplant, were receiving, or were in imminent need of RRT, were receiving comfort measures only, or had known infection with human immunodeficiency virus or active hepatitis. Written informed consent was provided by all patients or their legally authorized representatives prior to enrollment. The RUBY study was approved by the Western Institutional Review Board (Puyallup, WA) and by individual investigational review boards or ethics committees as required by each enrolling site.

The primary study endpoint was the development of persistent, severe AKI (stage 3), lasting for 72 h or more given that evidence demonstrates that the short and long-term risk of death or need for RRT is greatest for patients who persist with AKI for longer than 3 days \[[@CR4]\]. This primary endpoint is consistent with more recent studies on initiation of RRT which specified 72 h of oliguria as criterion for initiation of treatment \[[@CR12]\].

For the purposes of determining the primary endpoint, each patient's baseline serum creatinine was retrospectively adjudicated by a physician blinded to biomarker data based on serum creatinine data collected from the medical record from 6 months prior to enrollment through 3 months after enrollment. Patients not at stage 3 AKI at enrollment were required to reach stage 3 within 48 h and then persist in stage 3 AKI for at least 72 h to be considered endpoint positive. Patients who had a maximum AKI stage of 3 and died within 48 h of enrollment were also considered endpoint positive. Additionally, patients with stage 3 AKI who failed to achieve 72 consecutive hours due to initiation of RRT or death were considered endpoint positive (Fig. [1](#Fig1){ref-type="fig"}). The secondary endpoints were the composite of RRT initiation or death within 90 days and major adverse kidney events at 90 (± 7) days (MAKE~90~) \[[@CR13]\]. MAKE was defined as the composite of ≥ 25% loss in estimated glomerular filtration rate (eGFR), dialysis, or death. Estimated GFR was calculated from serum creatinine using the MDRD equation.Fig. 1Patient flow diagram. After exclusions, 331 patients with urinary CCL14 results were available for analysis. 110 patients met the persistent severe AKI endpoint (at least 72 consecutive hours of stage 3 AKI, initiation of dialysis, or death following stage 3 AKI)

Sample and data collection {#Sec4}
--------------------------

Blood and urine samples were collected at enrollment and centrifuged. Plasma (EDTA), serum, and urine supernatants were frozen within 2 h of sample collection, stored at ≤ − 70 °C, and thawed immediately prior to analysis. Patient data abstracted from the medical record included demographics, medical history, APACHE III variables, reason for admission, hourly urine output from the day prior to enrollment through study day 7, as well as serum creatinine, RRT, and death through 90 days after enrollment. Telephone follow-up was conducted at 90 (± 7) days to provide additional data for the MAKE~90~ endpoint.

Biomarker identification and testing {#Sec5}
------------------------------------

Potential candidate biomarkers from proteins associated with apoptosis, necrosis, endothelial injury, cell--cell and cell--matrix adhesion, cytoprotection, oxidative processes, cell-cycle regulation, inflammation, tubular injury, immune function, and fibrosis were selected for biologic plausibility based on previously described methods \[[@CR14]\]. The aim was to determine whether the candidate proteins could aid in risk assessment for persistence of renal dysfunction as well as contribute to the understanding behind the mechanisms of renal tissue damage and repair. A broad set of potential biomarkers were assessed focused on potential mechanisms of action as opposed to relying on defined AKI biomarkers alone.

Biomarkers were measured in urine and/or plasma at Astute Medical (San Diego, CA, USA) by technicians blinded to clinical data. Plasma and urinary NGAL were measured by enzyme-linked immunosorbent assay (Bioporto, Copenhagen, Denmark). The combination of tissue inhibitor of metallproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) was measured in urine with the NEPHROCHECK CCL14 Test (Astute Medical) as was the final analysis of urinary C--C motif chemokine ligand 14 (CCL14) using a prototype clinical immunoassay. Proenkephalin 119--159 was measured in plasma with sphingotest pro-ENK (sphingotec GmBH, Hennigsdorf, Germany). Other previously described biomarkers of AKI were measured on the Luminex 200 platform (Luminex, Austin, TX, USA) either with commercial kits from EMD Millipore (Billerica, MA, USA) \[urinary chitinase-3-like protein 1 (CHI3L1), plasma cystatin C, urinary liver fatty acid binding protein (L-FABP), urinary kidney injury molecule-1 (KIM-1)\] or with antibody pairs from R&D Systems (Minneapolis, MN, USA) \[glutathione *S*-transferase-pi (GST-pi), interleukin-18 (IL-18)\]. Creatinine was measured by LabCorp (Burlington, North Carolina, USA) using the Jaffe method in serum collected at the same time as urine and plasma collected for biomarker measurements.

Statistical analysis {#Sec6}
--------------------

A sample size of at least 300 patients was selected to achieve a half-width of the 95% CI ≤ 0.05 for the ROC AUC, providing a sufficiently narrow CI to assess biomarker efficacy. Continuous and categorical baseline variables were compared between endpoint negative and positive patients using the Wilcoxon rank-sum test and Fisher's exact test, respectively. Predictive ability of the biomarkers, including all combinations of two and three biomarkers (novel or previously described), for the primary endpoint of persistent severe AKI was assessed using the area under the receiver operating characteristic (ROC) curve. Confidence intervals of the area under the ROC curve (AUC) and pair-wise comparisons of AUC were calculated by the Delong method. Occurrence of MAKE~90~ was compared across CCL14 tertiles using the Cochran-Armitage test. The cumulative incidence curves for the composite of RRT initiation or death were estimated by the Kaplan--Meier method, and log-rank test was used to compare the groups. Statistical analyses were performed using R 3.5.1. Two-sided *p* values \< 0.05 were considered statistically significant. To examine whether CCL14 improved risk prediction beyond clinical variables alone, a reference multiple logistic regression model was constructed (Supplement) with those clinical variables significantly associated with the primary endpoint and further selected by a LASSO procedure. Integrated discrimination improvement (IDI) and category-free net reclassification improvement (cfNRI) were calculated with the "Hmisc" R package to assess the enhancement of risk prediction by the addition of CCL14 \[[@CR15]\].

Results {#Sec7}
=======

364 patients were enrolled in the RUBY study, of whom 331 (91%) were available for the primary analysis (Fig. [1](#Fig1){ref-type="fig"}). Approximately one-third (110 patients) of the analysis cohort met the primary endpoint of persistent stage 3 AKI, of whom 56 (51%) received RRT and 14 (13%) died prior to achieving 72 consecutive hours at stage 3. 113 patients (34%) met urine output criteria, 218 patients (66%) met serum creatinine criteria, and 53 (16%) patients met both criteria for stage 2--3 AKI at enrollment, with 45 (40%), 103 (47%), and 38 (72%) meeting the primary endpoint, respectively. Patients who developed persistent stage 3 AKI had a lower BMI and were less likely to have a history of diabetes mellitus but had higher serum creatinine values, fluid balance, and APACHE III scores at enrollment compared to patients who did not develop persistent stage 3 AKI (Table [1](#Tab1){ref-type="table"}). Patients who developed persistent stage 3 AKI were more likely to have stage 3 AKI at enrollment (64.5% vs 17.6%, *p* \< 0.001) which is consistent with higher enrollment levels of serum creatinine. Additionally, 128 (39%) patients met the secondary MAKE~90~ endpoint, of whom 108 (84%) were deceased, 13 (10%) had ≥ 25% loss in eGFR, and 7 (5%) were on dialysis at 90 (± 7) days.Table 1Baseline patient characteristics for all patients and by AKI persistence statusAll patientsNot persistent severe AKIPersistent severe AKI*p* valuePatients331221110Male207 (62.5%)136 (61.5%)71 (64.5%)0.631Age (years)64 (55--73)64 (54--73)64 (55--71)0.636Body mass index (kg/m^2^)29 (25--35)30 (26--36)28 (25--34)0.013Race0.371 Black or African American34 (10.3%)26 (11.8%)8 (7.3%) Other/unknown17 (5.1%)10 (4.5%)7 (6.4%) White or caucasian280 (84.6%)185 (83.7%)95 (86.4%)Chronic comorbidities Chronic kidney disease58 (17.5%)36 (16.3%)22 (20%)0.444 Diabetes mellitus109 (32.9%)82 (37.1%)27 (24.5%)0.025 Congestive heart failure74 (22.4%)51 (23.1%)23 (20.9%)0.677 Coronary artery disease117 (35.3%)84 (38%)33 (30%)0.179 Hypertension226 (68.3%)154 (69.7%)72 (65.5%)0.454 Chronic obstructive pulmonary disease55 (16.6%)35 (15.8%)20 (18.2%)0.639 Cancer84 (25.4%)57 (25.8%)27 (24.5%)0.894Reason for ICU admission Respiratory95 (28.7%)62 (28.1%)33 (30%)0.797 Surgery105 (31.7%)74 (33.5%)31 (28.2%)0.381 Cardiovascular148 (44.7%)96 (43.4%)52 (47.3%)0.558 Sepsis74 (22.4%)49 (22.2%)25 (22.7%)\> 0.999 Neurological16 (4.8%)12 (5.4%)4 (3.6%)0.593 Trauma7 (2.1%)6 (2.7%)1 (0.9%)0.432 Other107 (32.3%)74 (33.5%)33 (30%)0.536Vasopressors210 (63.4%)139 (62.9%)71 (64.5%)0.809Diuretics178 (53.8%)114 (51.6%)64 (58.2%)0.293Fluid balance (mL)3271 (1267--6422)2962 (1082--6028)3768 (1852--7353)0.037Days from ICU admission to enrollment1.1 (0.7--2.2)1.1 (0.7--2.4)1.2 (0.7--1.9)0.990Mechanical ventilation185 (55.9%)121 (54.8%)64 (58.2%)0.560Baseline serum creatinine (mg/dL)1 (0.8--1.2)1 (0.8--1.2)1 (0.8--1.3)0.083Enrollment serum creatinine (mg/dL)2.4 (1.7--3.3)2.1 (1.5--2.8)3.4 (2.6--4.2)\< 0.001Enrollment KDIGO Stage^a^\< 0.001 No AKI14 (4.2%)14 (6.3%)0 (0%) Stage 139 (11.8%)39 (17.6%)0 (0%) Stage 2168 (50.8%)129 (58.4%)39 (35.5%) Stage 3110 (33.2%)39 (17.6%)71 (64.5%)Enrollment non-renal APACHE III score54 (43--71)53 (41--69)58 (45--82)0.017^a^As determined by retrospective analysis

Of the biomarkers tested in this study, urinary C--C motif chemokine ligand 14 (CCL14) was most predictive of persistent stage 3 AKI with an AUC (95% CI) of 0.83 (0.78--0.87), which was significantly greater than the AUC values for the other biomarkers tested (Fig. [2](#Fig2){ref-type="fig"} and Table S1). Urinary CHI3L1 \[[@CR16]\], plasma cystatin C, plasma proenkephalin, urinary NGAL, and urinary L-FABP had AUC values between 0.70 and 0.75 (Fig. [2](#Fig2){ref-type="fig"}). Combinations of CCL14 with the other biomarkers did not significantly improve the AUC, with the exception of plasma cystatin C (AUC increase = 0.028, *p* = 0.04) (Table S2). For all biomarkers associated with AKI, concentrations increased with AKI stage (Fig. [3](#Fig3){ref-type="fig"}). Among patients who did not persist at any stage of AKI, the urinary CCL14 concentrations within different comorbid conditions were similar suggesting urinary CCL14 elevations were specific to AKI persistence. Of note, the other AKI biomarkers in Fig. [3](#Fig3){ref-type="fig"} showed substantial elevations in patients with some comorbid conditions even if they did not have persistent AKI.Fig. 2Area under the ROC curve (AUC) for prediction of persistent stage 3 AKI by urine CCL14 and other AKI biomarkers, including both injury and functional biomarkers. Biomarker concentrations were measured in urine and plasma samples collected at enrollment. The AUC for urine CCL14 was significantly (*p* \< 0.05) greater than for all other biomarkers shownFig. 3Biomarker concentrations for different non-AKI acute and chronic conditions and by severity of persistent AKI for **a** urine CCL14, **b** urine CHI3L1, **c** plasma cystatin C, **d** plasma proenkephalin, **e** urine NGAL, and **f** urine L-FABP. Open boxes are for different acute and chronic conditions among patients who did not persist at any stage of AKI. Shaded boxes are for patients by persistent AKI stage. Box and whiskers show interquartile ranges and total observed ranges (censored by 1.5 times the box range), respectively

Incidence of MAKE~90~ was 29%, 40%, and 47%, respectively, within the first, second, and third tertiles of CCL14 concentrations (*p* = 0.01). Mortality at 90 days also increased across CCL14 tertiles (*p* = 0.03), but the dialysis and eGFR loss components of MAKE~90~ did not significantly increase across CCL14 tertiles (Table S6). Cumulative incidence of the composite endpoint of RRT initiation or death within 90 days also increased across CCL14 tertiles (*p* \< 0.001), approximately doubling from 32 to 63% for the first to third tertile (Fig. [4](#Fig4){ref-type="fig"}). Most events (91%) occurred within the first 30 days after enrollment. The largest component of MAKE~90~ was mortality, which occurred in 108 (84%) of patients.Fig. 4Composite of RRT initiation or death for patients stratified by urine CCL14 tertile. Development of the composite endpoint increased across tertiles, log-rank *p* \< 0.001

Whether CCL14 enhances predictive ability over clinical variables was tested in a logistic regression model. Urinary CCL14 significantly improved risk prediction when added to a five-parameter clinical model for the primary endpoint, using ROC AUC, integrated discrimination improvement (IDI), and category-free net reclassification improvement (cfNRI) analyses (Tables S3 and S4). All analyses showed significant enhancement by the addition of CCL14 which remained strongly associated with the primary endpoint.

A sensitivity analysis on the definition of AKI persistence demonstrated consistent performance of CCL14 across persistence durations of 24, 48, 72, 96, and 120 h and progression windows of 24, 48, and 72 h (Table S5). The ROC AUC (95% CI) ranged from 0.79 (0.74--0.84) for 24 h persistence and progression within 24 h to 0.84 (0.79--0.88) for 48 h persistence and progression within 48 h. Moreover, a sensitivity analysis in which the 53 patients retrospectively determined not to be at KDIGO stage 2--3 at enrollment (Table [1](#Tab1){ref-type="table"}) were excluded showed nearly no change in the results for the primary endpoint \[AUC (95% CI) = 0.81 (0.76--0.86)\]. Among the patients not at KDIGO stage 2--3 at enrollment, 37 (70%) decreased from stage 2--3 by the time of enrollment, 10 (19%) were determined to have a lower KDIGO stage after adjudication of baseline serum creatinine, and 6 (11%) did not meet KDIGO criteria at any time.

Discussion {#Sec8}
==========

We have shown in a large international cohort of surgical and medical intensive care patients that several candidate molecules predict persistence of AKI, but that the best performing is a previously unknown candidate, urinary CCL14. Given this performance, we posit that CCL14 could be an important mediator of renal tissue damage and non-recovery. This is the first time such a finding has been described in AKI and the potential implications are considerable both for clinical management of patients with AKI and potential advancement of our understanding of the mechanism and potential therapeutic targets in AKI.

The results of the RUBY study have potential to be directly translatable to the clinical management of patients. A diagnostic test based on CCL14 which provides evidence of AKI persistence would aid in determining which patients may ultimately require RRT and which patients are likely to recover quickly and thus are unlikely to benefit from RRT initiation. Second, individuals highlighted as high risk for AKI persistence may be triaged to a referral center or to a higher level of care to mitigate potential complications of AKI, including emergent RRT. Third, identification of AKI persistence may allow for interventions to mitigate the important transition to CKD \[[@CR5]\].

Our results may help to advance the understanding of the mechanism of AKI and in particular pathways related to tissue damage and non-recovery of renal function. AKI is associated with renal inflammation and during this process, circulating monocytes are recruited, become activated and differentiate into macrophages. Both glomerular and interstitial macrophage infiltration can be observed following injury and macrophages seem to play a diverse role in kidney damage and repair \[[@CR17]\]. Indeed, in response to tissue injury, macrophages become activated with the functional state of the macrophage depending on the stage of tissue injury and repair. Therefore macrophages may contribute both to tissue injury and repair after AKI \[[@CR18]\]. Such macrophage polarization is dictated by the immediate microenvironment and appears to play a critical role in the recovery of renal function after AKI.

CCL14 is a member of the chemokine family of small molecules that were initially recognized for roles in leukocyte chemotaxis and are implicated in tissue injury and repair processes. CCL14 binds with high affinity to the chemokine receptors CCR1 and CCR5 and lower affinity to CCR3 \[[@CR19]\]. CCL14 has been shown to be an important chemokine for monocyte/macrophage recruitment and is associated with pro-inflammatory chemotaxis in a variety of diseases including rheumatoid arthritis, multiple sclerosis, and lupus \[[@CR20], [@CR21]\]. Little is known regarding the role and nature of CCL14 in AKI, presumably because CCL14 is not expressed in mice and rats, so cannot be studied in pre-clinical models using these animal models. However, because macrophage recruitment and polarization are believed to play important roles in kidney tissue damage and development of persistent kidney dysfunction \[[@CR17]\], a putative role for CCL14 can be proposed (Fig. [5](#Fig5){ref-type="fig"}). In addition, CCL14 has been shown to be an inflammatory marker identifying the risk of developing end-stage renal disease in diabetics \[[@CR22]\].Fig. 5Proposed CCL14 mechanism. **a** TNFα and other inflammatory mediators are released from injured epithelium and bind to TNF receptors, leading to release of CCL14 from tubular epithelial cells. **b** Binding of CCL14 to CCR1 and CCR5 receptors on monocytes and T cells induces chemotaxis towards site of injury. **c** Monocytes differentiate into macrophages and naïve T cells differentiate into proinflammatory Th1 cells

This proposed mechanism may explain the association of elevated levels of CCL14 with persistence of severe AKI and non-recovery. The amount of CCL14 secreted could reflect the extent of tissue damage. Moreover, higher levels of CCL14 may result in the recruitment of larger numbers of monocytes and T-cells which, in a pro-inflammatory injurious environment, can differentiate into M~1~ macrophages and Th1 cells that are pathogenic and can extend and magnify tissue damage. CCL14 could thus provide novel diagnostic and prognostic information that is important for managing patients with AKI, including decisions related to initiation of RRT. These assertions remain speculative and will require further investigation.

Our study has several strengths. First, this was an international multi-center trial that used the latest consensus guidelines to define the stage of AKI and persistent dysfunction \[[@CR5], [@CR10]\]. Second, all investigators and study personnel were unaware of the biomarker test results which were batched and measured centrally. Third, we measured a broad range of candidate kidney biomarkers in this study. Our study also has limitations. For example, the type of AKI (nephrotoxic, inflammatory, versus septic) was not adjudicated thus performance of various biomarkers may differ in subsets of AKI. In addition, the secondary outcome variable, MAKE~90~, was largely driven by mortality and the study had low inclusion to screening ratio. Lastly, the study had a small proportion of patients who were misclassified at enrollment.

In summary, our findings demonstrate that an elevation in urinary CCL14 predicts the persistence/progression of AKI in a large cohort of mixed critically ill patients with severe AKI. Consistent with pre-clinical studies, chemokine signaling and macrophage trafficking appear to play an important role in renal repair and recovery. Discovery of CCL14 as predictor of persistent AKI and thus, renal non-recovery may not only directly affect treatment options in the acute phase but offers the potential to identify new therapeutic approaches to AKI.
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